Aprea Therapeutics, Inc. (APRE) News
Follow Aprea Therapeutics, Inc. (APRE) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 10 public stories across 6 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
APRE - Aprea Therapeutics to Present Updated Interim Phase 1 Data on WEE1 Inhibitor APR-1051 in an Oral Presentation at 38th EORTC-NCI-AACR Symposium
APRE - Aprea Therapeutics to Present Updated Interim Phase 1 Data on WEE1 Inhibitor APR-1051 in an Oral Presentation at 38th EORTC-NCI-AACR Symposium
NEWS | Sep 22, 2026, 12:30 PM UTC
L
APRE: WEE1 inhibitor demonstrates promising efficacy and safety, with key data updates expected in Q4
The session highlighted progress in synthetic lethality oncology, with a WEE1 inhibitor showing promising efficacy and safety in biomarker-defined cancers. Dose escalation established 150 mg as the minimum efficacious do
NEWS | Sep 14, 2026, 10:12 PM UTC
L
APRE: Promising WEE1 inhibitor shows efficacy and safety in biomarker-driven cancer trials
A precision oncology company presented clinical progress on its WEE1 inhibitor, showing promising efficacy and safety in biomarker-defined cancers, with further data and expansion cohorts expected later this year. The pi
NEWS | Sep 14, 2026, 09:20 PM UTC
L
Aprea Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference
DOYLESTOWN, Pa., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. NASDAQ:APRE (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targe
EQUITY | Sep 10, 2026, 12:03 PM UTC
L
APRE - Aprea Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference
APRE - Aprea Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference
EQUITY | Sep 10, 2026, 12:00 PM UTC
L
Aprea expands IP portfolio with 28 issued and 30 pending patents
Aprea expanded its IP portfolio, citing 28 issued and 30 pending patents and extending WEE1 and ATR protections.
EQUITY | Aug 28, 2026, 12:34 PM UTC
L
Aprea Therapeutics expands IP portfolio for precision oncology programs
Aprea Therapeutics announced an expansion of its intellectual property portfolio for precision oncology programs.
EQUITY | Aug 28, 2026, 12:17 PM UTC
L
APRE - Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs
APRE - Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs
EQUITY | Aug 28, 2026, 12:15 PM UTC
L
Aprea Therapeutics Announces Q2 2026 Results
Aprea Therapeutics announces second quarter 2026 financial results
EARNINGS | Aug 12, 2026, 12:30 PM UTC
M
Aprea Therapeutics Accelerates APR-1051 Enrollment
Aprea accelerates APR-1051 clinical trial enrollment
EQUITY | Jul 30, 2026, 12:01 PM UTC